Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.3%

3 terminated out of 41 trials

Success Rate

89.3%

+2.8% vs benchmark

Late-Stage Pipeline

17%

7 trials in Phase 3/4

Results Transparency

32%

8 of 25 completed with results

Key Signals

8 with results89% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (30)
P 2 (2)
P 3 (2)
P 4 (5)

Trial Status

Completed25
Recruiting5
Terminated3
Withdrawn3
Unknown3
Active Not Recruiting1

Trial Success Rate

89.3%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT05238142Not ApplicableCompletedPrimary

In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

NCT05795439Not ApplicableRecruiting

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

NCT06579404Not ApplicableRecruitingPrimary

Closed-loop in Adults With Type 2 Diabetes

NCT05785832Not ApplicableCompletedPrimary

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT06185296Not ApplicableRecruitingPrimary

The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy

NCT06268808Not ApplicableCompletedPrimary

Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy

NCT07063420Not ApplicableRecruitingPrimary

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers

NCT05893797Not ApplicableCompleted

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

NCT05317585Not ApplicableRecruitingPrimary

Continuous Glucose Monitor Use in Pregnancy

NCT05462756Phase 3Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

NCT03070106Not ApplicableCompleted

Diabetes: Functional Medicine Approach Vs. Usual Care

NCT04585191Not ApplicableCompletedPrimary

Reducing Treatment Risk in Older Adults With Diabetes

NCT06473662Phase 2CompletedPrimary

Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects

NCT06311019Not ApplicableActive Not RecruitingPrimary

The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections

NCT06119204Not ApplicableTerminatedPrimary

SAFE-LCD Trial, for Insulin-treated Adults Living With Type 2 Diabetes

NCT06268821Not ApplicableTerminatedPrimary

Effect on HbA1c of the Initiation of CGM in Adults With Type 2 Diabetes Treated With Basal Insulin in Finland

NCT06519903Not ApplicableCompleted

Anxiety Reduction in Type 2 Diabetes Through Breathing ExercisesPatients With Type 2 Diabetes

NCT04460326Phase 3CompletedPrimary

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT05111301Not ApplicableCompletedPrimary

Control-IQ Technology in Individuals With Type 2 Diabetes

NCT04274660Not ApplicableCompleted

Evaluation of Diabetes and WELLbeing Programme

Scroll to load more

Research Network

Activity Timeline